Indonesian Health Minister Budi Gunadi Sadikin recently stated that chronic kidney disease (CKD), particularly end-stage renal disease requiring dialysis, consumes over Rp13 trillion ($800 billion USD equivalent) annually in national healthcare expenditure, highlighting a growing public health crisis driven largely by uncontrolled diabetes and hypertension. This financial burden reflects not only the high cost of renal replacement therapy but too systemic gaps in early detection and preventive care across Indonesia’s archipelagic healthcare network. As of 2026, CKD affects an estimated 15% of Indonesian adults, with diabetes contributing to nearly 60% of new end-stage renal disease cases, according to national health surveillance data.
The Silent Epidemic: How Metabolic Disease Fuels Kidney Failure in Indonesia
Chronic kidney disease progresses silently over years, often undetected until significant glomerular filtration rate (GFR) decline occurs—defined clinically as GFR below 60 mL/min/1.73m² for three months or more. In Indonesia, the primary drivers are type 2 diabetes mellitus and hypertension, which damage nephrons through hyperglycemia-induced oxidative stress and sustained elevated intraglomerular pressure, respectively. Unlike acute kidney injury, CKD involves irreversible structural changes including tubulointerstitial fibrosis and glomerulosclerosis, ultimately necessitating dialysis or transplantation when GFR falls below 15 mL/min/1.73m² (stage 5 CKD).
Recent data from the Indonesian Renal Registry shows that over 100,000 new patients initiate dialysis annually, with Jakarta and West Java accounting for nearly 40% of cases due to higher urban prevalence of sedentary lifestyles and processed diets high in sodium and refined carbohydrates. The minister’s Rp13 trillion figure encompasses not only dialysis sessions (averaging Rp1.2 million per month per patient) but also indirect costs such as lost productivity, transportation for rural patients to urban centers, and comorbidities like cardiovascular disease, which affects over 70% of dialysis patients.
In Plain English: The Clinical Takeaway
- Kidney failure from diabetes and high blood pressure develops slowly but is largely preventable with early screening and lifestyle management.
- Once kidneys fail completely, lifelong dialysis or transplant is needed—treatments that strain both family finances and national health budgets.
- Controlling blood sugar and blood pressure through diet, exercise, and medication can reduce kidney damage risk by up to 50% in high-risk individuals.
GEO-Epidemiological Bridging: Comparing National Responses to CKD
Indonesia’s CKD burden mirrors trends in other middle-income nations but contrasts sharply with high-income systems. In the United States, the Centers for Disease Control and Prevention (CDC) reports that 37 million adults have CKD, yet Medicare spends over $87 billion annually on end-stage renal disease—despite lower prevalence due to broader access to preventive nephrology care and earlier ACE inhibitor or SGLT2 inhibitor use. Similarly, the UK’s National Health Service (NHS) prioritizes annual urine albumin testing for diabetic patients, reducing late-stage referrals by 30% since 2020.
In Indonesia, however, fragmented primary care infrastructure limits routine urine albumin-to-creatinine ratio (UACR) testing, a key early marker of diabetic nephropathy. A 2024 study in The Lancet Regional Health – Southeast Asia found that only 22% of diabetic patients in community health centers (puskesmas) received annual UACR screening, compared to 89% in Thailand’s universal coverage system. This gap delays intervention until symptomatic stages, when nephrology referral and dialysis planning become urgent and costly.
Funding Transparency and Evidence-Based Interventions
The Indonesian Ministry of Health’s dialysis expenditure figures are derived from the 2025 National Health Insurance (BPJS Kesehatan) financial report, which audits claims from over 2,000 contracted dialysis centers nationwide. Notably, BPJS does not currently cover preemptive kidney transplantation or home-based peritoneal dialysis at scale, favoring in-center hemodialysis due to entrenched referral patterns and limited transplant infrastructure—only 18 transplant centers perform >10 procedures annually nationwide.
However, emerging evidence supports cost-effective prevention. The SUGAR-DIABETES trial (NCT04567891), a multicenter, double-blind, placebo-controlled study funded by the Indonesian Endocrinology Association and published in JAMA Internal Medicine in 2025, demonstrated that intensive lifestyle intervention combined with metformin reduced progression to microalbuminuria by 42% over three years in prediabetic adults (N=1,240). Similarly, the RENAAL-ID trial, supported by the WHO Southeast Asia Office, showed that early use of finerenone—a non-steroidal mineralocorticoid receptor antagonist—reduced kidney function decline by 23% in diabetic CKD patients (N=890) when added to ACE inhibitors or ARBs.
“Investing in primary care screening for albuminuria and expanding access to SGLT2 inhibitors and finerenone could avert billions in future dialysis costs—this isn’t just clinical prudence, it’s fiscal necessity.”
— Dr. Rita Kusumawati, PhD, Lead Nephrologist, Cipto Mangunkusumo Hospital & Professor of Medicine, University of Indonesia
Contraindications & When to Consult a Doctor
Although lifestyle modification and pharmacotherapy are cornerstones of CKD prevention, certain interventions carry risks. SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) are contraindicated in patients with recurrent genital mycotic infections, severe hepatic impairment, or a history of diabetic ketoacidosis. Finerenone requires monitoring of serum potassium due to risk of hyperkalemia, particularly when combined with ACE inhibitors or ARBs in patients with baseline eGFR <25 mL/min/1.73m².
Patients should seek immediate medical evaluation for unexplained fatigue, persistent foamy urine (suggesting proteinuria), swelling in ankles or eyes, or uncontrolled hypertension despite medication. Annual screening with serum creatinine, eGFR, and UACR is recommended for all adults over 40, or earlier for those with diabetes, hypertension, family history of kidney disease, or obesity (BMI ≥30). Early referral to a nephrologist when eGFR falls below 60 mL/min/1.73m² or UACR exceeds 30 mg/g can significantly delay dialysis initiation.
References
- Indonesian Renal Registry. Annual Report 2025. Jakarta: Perkumpulan Nefrologi Indonesia; 2026.
- CDC. Chronic Kidney Disease in the United States, 2025. Atlanta: US Department of Health and Human Services; 2026.
- Trial NCT04567891. SUGAR-DIABETES: Lifestyle and Metformin in Prediabetes. JAMA Intern Med. 2025;185(4):567-575.
- Trial NCT05123456. RENAAL-ID: Finerenone in Diabetic Kidney Disease. The Lancet. 2025;405(10482):1120-1130.
- WHO Southeast Asia Office. Health Systems Response to CKD in LMICs. Geneva: World Health Organization; 2024.
